Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2007

01-07-2007 | Clinical Trial

Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy

Authors: Daniel H. S. Silverman, Christine J. Dy, Steven A. Castellon, Jasmine Lai, Betty S. Pio, Laura Abraham, Kari Waddell, Laura Petersen, Michael E. Phelps, Patricia A. Ganz

Published in: Breast Cancer Research and Treatment | Issue 3/2007

Login to get access

Abstract

Purpose To explore the relationship of regional cerebral blood flow and metabolism with cognitive function and past exposure to chemotherapy for breast cancer.
Patients and methods Subjects treated for breast cancer with adjuvant chemotherapy remotely (5–10 years previously) were studied with neuropsychologic testing and positron emission tomography (PET), and were compared with control subjects who had never received chemotherapy. [O-15] water PET scans was acquired during performance of control and memory-related tasks to evaluate cognition-related cerebral blood flow, and [F-18] fluorodeoxyglucose (FDG) PET scans were acquired to evaluate resting cerebral metabolism. PET scans were analyzed by statistical parametric mapping and region of interest methods of analysis.
Results During performance of a short-term recall task, modulation of cerebral blood flow in specific regions of frontal cortex and cerebellum was significantly altered in chemotherapy-treated subjects. Cerebral activation in chemotherapy-treated subjects differed most significantly from untreated subjects in inferior frontal gyrus, and resting metabolism in this area correlated with performance on a short-term memory task previously found to be particularly impaired in chemotherapy-treated subjects. In examining drug-class specific effects, metabolism of the basal ganglia was significantly decreased in tamoxifen + chemotherapy-treated patients compared with chemotherapy-only breast cancer subjects or with subjects who had not received chemotherapy, while chemotherapy alone was not associated with decreased basal ganglia activity relative to untreated subjects.
Conclusion Specific alterations in activity of frontal cortex, cerebellum, and basal ganglia in breast cancer survivors were documented by functional neuroimaging 5–10 years after completion of chemotherapy.
Literature
1.
Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics. CA Cancer J Clin 55:10–30PubMedCrossRef
2.
Ganz PA (2002) What outcomes matter to patients: a physician-researcher point of view. MedCare 40:III11-III19
3.
Phillips KA, Bernhard J (2003) Adjuvant breast cancer treatment and cognitive function: current knowledge and research directions. J Natl Cancer Inst 95:190–197PubMedCrossRef
4.
Ahles TA, Saykin A (2001) Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Invest 19:812–820PubMedCrossRef
5.
Meyers CA (2000) Neurocognitive dysfunction in cancer patients. Oncology 14:75–79PubMed
6.
Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla IK, Whedon MB, Bivens S, Mitchell T, Greenberg ER, Silberfarb PM (2002) Neuropsychologic impact of standard-dose systemic chemotherapy in long- term survivors of breast cancer and lymphoma. J Clin Oncol 20:485–493PubMedCrossRef
7.
Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF (2000) Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 18:2695–2701PubMed
8.
Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA (2004) Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 26:955–69PubMedCrossRef
9.
Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF (1999) Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85:640–650PubMedCrossRef
10.
Tchen N, Juffs HG, Downie FP, Qi-Long Y, Hu H, Chemerynsky I, Clemons M, Crump M, Goss PE, Warr D, Tweedale ME, Tannock IF (2003) Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology, 21:4175–4183PubMedCrossRef
11.
van Dam FS, Schagen SB, Muller MJ, Boogerd W, Wall E, Droogleever Fortuyn ME, Rodenhuis S (1998) Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90:210–218PubMedCrossRef
12.
Wieneke MH, ER Dienst (1995) Neuropsychological Assessments of Cognitive Functioning Following Chemotherapy for Breast Cancer. Psycho-Oncology 4:61–66CrossRef
13.
Wefel JS, Lenzi R, Theriault RL, Meyers CA (2004) The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized, longitudinal trial. Cancer 100:2292–2299PubMedCrossRef
14.
Arpels JC (1996) The female brain hypoestrogenic continuum from the premenstrual syndrome to menopause. A hypothesis and review of supporting data. J Reprod Med 41:633–639PubMed
15.
Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S (2004) Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology 13:61–66PubMedCrossRef
16.
Paganini-Hill A, Clark LJ (2000) Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 64:165–176PubMedCrossRef
17.
Silverman DHS, Alavi A (2005) PET imaging in the assessment of normal and impaired cognitive function. Radiologic Clin North Am Saunders/Elsevier, Philadelphia, 43:67–77
18.
Lai J, Dy CJ, Pio BS, Ganz PA, Castellon SA, Abraham L, Waddell K, Phelps ME, Bookheimer SY, Silverman DHS (2005) Anterior cingulate and temporal lobe regions associated with congruence of memory recall to mood. J Nucl Med 46(5, abstr. suppl):no. 29
19.
Rasgon NL, Silverman D, Siddarth P, Miller K, Ercoli LM, Elman S, Lavretsky H, Huang S-C, Phelps PE, Small GW (2005) Estrogen use and brain metabolic change in postmenopausal women with age-associated memory decline. Neurobiology of Aging 226:229–235CrossRef
20.
Talairach J, Tournoux P (1988) Co-planar stereotaxic atlas of the human brain. 3-dimensional proportional system: An approach to cerebral imaging. New York: Thieme
21.
Friston K, Ashburner J, Heather J, et al (2003) Statistical Parametric Mapping (SPM2). Available at www.fil.ion.ucl.ac.uk/spm (The Wellcome Department of Cognitive Neurology, University College London, London)
22.
Partridge AH, Burstein HJ, Winer EP (2001) Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr 135–142
23.
Ganz PA (2001a) Impact of tamoxifen adjuvant therapy on symptoms, functioning, and quality of life. J Natl Cancer Inst Monogr 130–134
24.
Shapiro CL, Recht A (2001) Side Effects of Adjuvant Treatment of Breast Cancer. N Engl J Med 344:1997–2008PubMedCrossRef
25.
Ganz PA, Hirji K, Sim MS, Schag CA, Fred C, Polinsky ML (1993) Predicting psychosocial risk in patients with breast cancer. Med Care 31:419–431PubMedCrossRef
26.
Schag CA, Ganz PA, Polinsky ML, Fred C, Hirji K, Petersen L (1993) Characteristics of women at risk for psychosocial distress in the year after breast cancer. J Clin Oncol 11:783–793PubMed
27.
Ganz PA, Desmond KA, Belin TR, Meyerowitz BE, Rowland JH (1999) Predictors of sexual health in women after a breast cancer diagnosis. J Clin Oncol 17:2371–2380PubMed
28.
Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE (1998a) Life after breast cancer: understanding women’s health-related quality of life and sexual functioning. J Clin Oncol 16:501–514
29.
Rowland JH, Desmond KA, Meyerowitz BE, Belin TR, Wyatt GE, Ganz PA (2000) Role of breast reconstructive surgery in physical and emotional outcomes among breast cancer survivors. J Natl Cancer Inst 92:1422–1429PubMedCrossRef
30.
Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Belin TR (2000) Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol 18:743–753PubMed
31.
Ganz PA, Rowland JH, Meyerowitz BE, Desmond KA (1998b) Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors. Recent Results Cancer Res 152:396–411
32.
Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B, Belin TR (2000) Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Natl Cancer Inst 92:1054–1064PubMedCrossRef
33.
Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR (2002) Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 94:39–49PubMed
34.
Loprinzi CL, Thome SD (2001) Understanding the Utility of Adjuvant Systemic Therapy for Primary Breast Cancer. J Clin Oncol 19:972–979PubMed
35.
Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL (2001) Computer Program to Assist in Making Decisions About Adjuvant Therapy for Women With Early Breast Cancer. J Clin Oncol 19:980–991PubMed
36.
Ganz PA (1998) Cognitive dysfunction following adjuvant treatment of breast cancer: a new dose-limiting toxic effect? J Natl Cancer Inst 90:182–183 PubMedCrossRef
37.
Castellon SA, Silverman DHS, Ganz P (2005) Breast cancer treatment and cognitive functioning: current status and future challenges in assessment. Breast Cancer Research and Treatment 92:199–206PubMedCrossRef
38.
Eberling JL, Wu C, Tong-Turnbeaugh R, Jagust WJ (2004) Estrogen- and tamoxifen-associated effects on brain structure and function. Neuroimage 21:364–371PubMedCrossRef
39.
Block RI, O’Leary DS, Hichwa RD, Augustinack JC, Ponot LLB, Ghoneim MM, Arndt S, Hurtig RR, Watkins GL, Hall JA, Nathan PE, Andreasen NC (2002) Effects of frequent marijuana use on memory-related regional cerebral blood flow. Pharmacol Biochem Behav 72:237–250PubMedCrossRef
40.
Schmamann JD, ed: The cerebellum and cognition. Academic Press, San Diego, 1997
41.
Silverman DHS and Melega WP (2004) Molecular imaging of biological processes with PET: evaluating biologic bases of cerebral function. In PET: Molecular Imaging and Its Biological Applications ME Phelps, ed., Springer-Verlag, New York, pp. 509–583
42.
Tran A, Pio BS, Khatibi B, Czernin J, Phelps ME, Silverman DHS (2005) 18F-FDG PET for staging breast cancer in patients with inner-quadrant versus outer-quadrant tumors: comparison with long-term clinical outcome. J Nucl Med 46:1455–1459PubMed
43.
Ciocca DR, Roig LM (1995) Estrogen receptors in human nontarget tissues: biological and clinical implications. Endocr Rev 16:35–62PubMedCrossRef
44.
Hampson E (1990) Variations in sex-related cognitive abilities across the menstrual cycle. Brain Cogn 14:26–43PubMedCrossRef
45.
Komenich PKD, Lane M, Dickey RP, Stone SC (1978) Gonadal hormones and cognitive performance. Physiological Psychology 6:115–120
46.
Jacobs DM, Tang MX, Stern Y, Sano M, Marder K, Bell KL, Schofield P, Dooneief G, Gurland B, Mayeux R (1998) Cognitive function in nondemented older women who took estrogen after menopause. Neurology 50:368–373PubMed
47.
McLay RN, Maki PM, Lyketsos CG (2003) Nulliparity and late menopause are associated with decreased cognitive decline. Journal of Neuropsychiatry and Clinical Neurosciences 15:161–167PubMed
48.
Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A, Bacal C, Lingle DD, Metter E (1997) A prospective study of estrogen replacement therapy and the risk of developing Alzheimer’s disease: the Baltimore Longitudinal Study of Aging. Neurology 48:1517–1521PubMed
49.
Paganini-Hill A, Henderson VW (1996) Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 156:2213–2217PubMedCrossRef
50.
Maki PM, Resnick SM (2000) Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition. Neurobiology of Aging 21(2):373–83PubMedCrossRef
51.
Shaywitz SE, Shaywitz BA, Pugh KR, et al (1999) Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA 281:1197–202PubMedCrossRef
52.
LeBlanc ES, Janowsky J, Chan BK, Nelson HD (2001) Hormone replacement therapy and cognition: systematic review and meta- analysis. JAMA 285:1489–1499PubMedCrossRef
53.
Haskell SG, Richardson ED, Horwitz RI (1997) The effect of estrogen replacement therapy on cognitive function in women: a critical review of the literature. J Clin Epidemiol 50:1249–1264PubMedCrossRef
54.
Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones III BN, Assaf AR, Jackson RD, Morley Kotchen J, Wassertheil-Smoller S, Wactawski-Wende J (2003) Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women’s Health Initiative Memory Study: A Randomized Controlled Trial. JAMA 289:2651PubMedCrossRef
55.
Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass MLS, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M, Bowen D (2003) Effect of Estrogen Plus Progestin on Global Cognitive Function in Postmenopausal Women: The Women’s Health Initiative Memory Study: A Randomized Controlled Trial. JAMA 289:2663PubMedCrossRef
56.
57.
Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, Pollmacher T (2001) Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 58:445–452PubMedCrossRef
58.
Lerner DM, Stoudemire A, Rosenstein DL (1999) Neuropsychiatric toxicity associated with cytokine therapies. Psychosomatics 40:428–435PubMed
59.
Denicoff KD, Rubinow DR, Papa MQ, Simpson C, Seipp CA, Lotze MT, Chang AE, Rosenstein D, Rosenberg SA (1987) The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 107:293–300PubMed
60.
Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P (1998) Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 25:39–47PubMed
61.
Capuron L, Ravaud A, Gualde N, Bosmans E, Dantzer R, Maes M, Neveu PJ (2001) Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 26:797–808PubMedCrossRef
62.
Singh VK, Guthikonda P (1997) Circulating cytokines in Alzheimer’s disease. J Psychiatr Res 31:657–660PubMedCrossRef
63.
Holmes C, El-Okl M, Williams AL, Cunningham C, Wilcockson D, Perry VH (2003) Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer’s disease. J Neurol Neurosurg Psychiatry Jun;74(6):788–9
64.
Papassotiropoulos A, Bagli M, Jessen F, Bayer RA, Maier W, Rao ML, Heun R (1999) A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer’s disease. Ann Neurol 45:666–668PubMedCrossRef
65.
Weaver JD, Huang MH, Albert M, Harris T, Rowe JW, Seeman TE (2002) Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology 59:371–378PubMed
66.
Maier SF (2003) Bi-directional immune-brain communication: Implications for understanding stress, pain, and cognition. Brain, Behavior & Immunity 17:69–85CrossRef
67.
Pugh RC, Fleshner M, Watkins LR, Maier SF, Rudy JW (2001) The immune system and memory consolidation: A role for the cytokine IL-1beta. Neuroscience & Biobehavioral Reviews 25:29–41CrossRef
68.
Blair JR, Spreen O: Predicting pre-morbid IQ (1989) a revision of the National Adult Reading Test. The Clinical Neuropsychologist, 3:129–136
Metadata
Title
Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy
Authors
Daniel H. S. Silverman
Christine J. Dy
Steven A. Castellon
Jasmine Lai
Betty S. Pio
Laura Abraham
Kari Waddell
Laura Petersen
Michael E. Phelps
Patricia A. Ganz
Publication date
01-07-2007
Published in
Breast Cancer Research and Treatment / Issue 3/2007
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-006-9380-z

Other articles of this Issue 3/2007

Breast Cancer Research and Treatment 3/2007 Go to the issue

Epidemiology

Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil

Review Paper

Is cognitive dysfunction a complication of adjuvant chemotherapy in the older patient with breast cancer?

Clinical Trial

Differentially expressed genes between primary cancer and paired lymph node metastases predict clinical outcome of node-positive breast cancer patients

Epidemiology

Melatonin and estrogen in breast cyst fluids

Clinical Trail

Prediction of response to repeat utilization of anthracycline in recurrent breast cancer patients previously administered anthracycline-containing chemotherapeutic regimens as neoadjuvant or adjuvant chemotherapy

EPIDEMIOLOGY

CDKN2A-positive breast cancers in young women from Poland
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits